Table 1.
Patients characteristics at baseline per treatment group
| Prednisolone | Dexamethasone | Methylprednisolone | Total | p value | |
|---|---|---|---|---|---|
| Inclusion, N (%) | 67 (54%) | 37 (30%) | 21 (17%) | 125 (100%) | |
| The Netherlands | 6 | 37 | 0 | 43 | |
| Serbia | 57 | 0 | 1 | 58 | |
| Italy | 4 | 0 | 20 | 24 | |
| Male, N (%) | 41 (61%) | 29 (78%) | 15 (71%) | 85 (68%) | 0.18 |
| Mean age (SD) | 51.1 (18) | 55.6 (14) | 57.1 (14) | 53.4 (16) | 0.20 |
| Walking unassisted, N (%) | 47 (70%) | 33 (89%) | 20 (95.5%) | 100 (80%) | 0.01a |
| Median MRC sum score (range) | 50 (34–60) | 56 (46–60) | 57 (42–60) | 53 (34–60) | 0.003a |
| CIDP subtype, N (%) | Typical: 58 (87%) Atypical: 9 (13%) (MADSAM 3, DADS 2, pure motor 4) |
Typical: 28 (76%) Atypical: 9 (24%) (MADSAM 5, pure sensory 3, pure motor 1) |
Typical: 12 (57%) Atypical: 9 (43%) (MADSAM 4, DADS 2, pure sensory 3) |
Typical: 98 (78%) Atypical: 27 (22%) (MADSAM 12, DADS 4, pure sensory 6, pure motor 5) |
0.03a |
MRC Medical Research Council sum score (six paired muscle groups), MADSAM multifocal acquired demyelinating sensory and motor neuropathy, DADS distal-acquired demyelinating symmetric polyneuropathy
aPost hoc analysis